Helen C. Adams, Director at Prometheus Biosciences, Inc. (RXDX), bought 500 shares at $19.00 ($10K) on 2021-03-16, disclosed to the SEC on 2021-03-16.
Open-market purchase of $10k RXDX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.